Aldosterone in heart disease

Current Hypertension Reports

Volumn 14, Issue 2, 2012, Pages 125-129

  Mihailidou, Anastasia S ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Aldosterone; Arrhythmia; Cortisol; Heart failure; Hypertension; Mineralocorticoid receptor; Na K ATPase; Primary aldosteronism; Redox state; Sodium

Indexed keywords

ALDOSTERONE; ALDOSTERONE RECEPTOR; HYDROCORTISONE; MIFEPRISTONE; MINERALOCORTICOID RECEPTOR; SODIUM; SODIUM CHLORIDE; SPIRONOLACTONE;

ALDOSTERONE BLOOD LEVEL; ARTICLE; BLOOD PRESSURE REGULATION; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART INJURY; HEART PROTECTION; HUMAN; HYPERTENSION; KIDNEY INJURY; LOW DRUG DOSE; MORBIDITY; MORTALITY; NONHUMAN; OXIDATION REDUCTION STATE; PATHOGENESIS; PHARMACOLOGICAL BLOCKING; PREDICTION; RISK ASSESSMENT; SALT INTAKE;

ARRHYTHMIAS, CARDIAC; HEART FAILURE; HUMANS; HYDROCORTISONE; HYPERALDOSTERONISM; HYPERTENSION; RECEPTORS, MINERALOCORTICOID; SODIUM, DIETARY;

EID: 84861096429     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-012-0256-9     Document Type: Article

References (38)

1. Simpson SA, Tait JF, Wettstein A, et al. Isolierung eines neuen kristallisierten Hormons aus Nebennerien mit besonders hoher Wirksamkeit auf denMineralsoffwechsel. Experientia. 1953;9:333-5.
2. Beygui F, Collet J-P, Benoliel J-J, et al. High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction. Circulation. 2006;114:2604-10. (Pubitemid 44967343)
3. Beygui F, Montalescot G, Vicaut E, et al. Aldosterone and longterm outcome after myocardial infarction: A substudy of the French nationwide Observatoire sur la Prise en charge hospitalière, l'Evolution à un an et les caRactéristiques de patients présentant un infArctus du myocarde avec ou sans onde Q (OPERA) study. Am Heart J. 2009;157(4):680-7.
4. Weir RAP, Tsorlalis IK, Steedman T, et al. Aldosterone and cortisol predict medium-term left ventricular remodelling following myocardial infarction. Eur J Heart Failure. 2011;13:1305-13.
5. Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens. 2002;15:709-16. (Pubitemid 34804277)
6. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003;16:925-30. (Pubitemid 37315491)
7. Chapman N, Dobson J, Wilson S, et al. Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007;49:839-45. (Pubitemid 351664214)
8. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-17. (Pubitemid 29407370)
9. Pitt B, Remme W, Zannad F, et al. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-21. (Pubitemid 36384098)
10. Zannad F, McMurray JJ, Krum H, et al.; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11-21.
11. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation. 1990;82:1730-6. (Pubitemid 20367976)
12. Vantrimpont P, Rouleau JL, Ciampi A, et al. Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) Study. Eur Heart J. 1998;19:1552-63. (Pubitemid 28470478)
13. Güder G, Bauersachs J, Frantz S, et al. Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation. 2007;115:1754-61. (Pubitemid 46648612)
14. Brilla CG, Matsubara LS, Weber KT. Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol. 1993;71:12A-6A. (Pubitemid 23046406)
15. Young M, Fullerton M, Dilley R, Funder J. Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest. 1994;93:2578-80.
16. Wang Q, Clement S, Gabbiani G. Chronic hyperaldosteronism in a transgenic mouse model fails to induce cardiac remodeling and fibrosis under a normal-salt diet. Am J Physiol Renal Physiol. 2004;286:F1178-84. (Pubitemid 38656375)
17. Pimenta E, Gordon RD, Ahmed AH, et al. Cardiac dimensions are largely determined by dietary salt in patients with primary aldosteronism: results of a case control study. J Clin Endocrinol Metab. 2011;96:2813-2820.
18. Rocha R, Rudolph AE, Frierdich GE. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol. 2002;283:H1802-10. (Pubitemid 35217013)
19. Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2008;93:3266-81.
20. Shibata S, Mu S, Kawarazaki H, Muraoka K., et al. Rac1 GTPase in rodent kidneys is essential for salt-sensitive hypertension via a mineralocorticoid receptor-dependent pathway. J Clin Invest. 2011;121:3233-3243.
21. Shibata S, Nagase M, Yoshida S, et al. Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med. 2008;14:1370-6.
22. Nagase M, Ayuzawa N, Kawarazaki W, et al. Oxidative stress causes mineralocorticoid receptor activation in rat cardiomyocytes: role of small GTPase Rac1. Hypertension 2012 Jan 9 (Epub ahead of print).
23. Noble D. Ionic mechanisms determining the timing of ventricular repolarization: significance for cardiac arrhythmias. Ann N YAcad Sci. 1992;644:1-22.
24. Ouvrard-Pascaud A, Sainte-Marie Y, Bénitah J-P, et al. Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation. 2005;11:3025-33. (Pubitemid 40847778)
25. Pieske B, Maier LS, Piacentino V, et al. Rate dependence of [Na+]i and contractility in nonfailing and failing human myocardium. Circulation. 2002;106:447-53. (Pubitemid 34803689)
26. Mihailidou AS, Bungaard H,MardiniM, et al. Hyperaldosteronemia in rabbits inhibits the cardiac sarcolemmal Na + -K + pump. Circ Res. 2000;86:37-42. (Pubitemid 30044166)
27. Komentiani P, Li J, Gnudi L, et al. Multiple signal transduction pathways link Na+/K + -ATPase to growth-related genes in cardiac myocytes. J Biol Chem. 1998;24:15249-56.
28. Kent RL, Hoober K, Cooper IV G. Load responsiveness of protein synthesis in adult mammalian myocardium: role of cardiac deformation linked to sodium influx. Circ Res. 1989;64:74-85. (Pubitemid 19028505)
29. Huang L, Kometiani P, Xie Z. Differential regulation of Na/K-ATPase a-subunit isoform gene expressions in cardiac myocytes by ouabain and other hypertrophic stimuli. J Mol Cell Cardiol. 1997;29:3157-67. (Pubitemid 27510781)
30. Ivanes F, Susen S, Mouquet F, et al. Aldosterone, mortality, and acute ischaemic events in coronary artery disease patients outside the setting of acute myocardial infarction or heart failure. Eur Heart J. 2012;33:191-202.
31. Rousseau MF, Gurne O, Duprez D, et al. Beneficial neurohormonal profile of spironolactone in severe congestive heart failure. JAmColl Cardiol. 2002;40:1596-601.
32. Le TYL, Ashton A, Mardini M, Funder JW, Mihailidou AS. Cardioprotective action of mineralocorticoid receptor antagonists during experimental myocardial infarction: role of Apoptosis Repressor with Caspase recruitment domain (ARC). Hypertension. 2011;58:117 (Abstract 13).
33. Krozowski ZS, Funder JW. Renal mineralocorticoid receptors and hippocampal corticosterone-binding species have identical intrinsic steroid specificity. Proc Natl Acad Sci. 1983;80:6056-60. (Pubitemid 14228243)
34. Arriza JL, Weinberger C, Cerelli G, et al. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science. 1987;237:268-75. (Pubitemid 17095145)
35. Nagata K, Obata K, Xu J, et al. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension. 2006;47:656-64. (Pubitemid 43740235)
36. Mihailidou, AS, Mardini M, Fraser T, et al. Agonist/antagonist activity of cortisol in cardiomyocyte mineralocorticoid receptors is determined by redox state. Presented at the International Aldosterone Conference, New Orleans, 2004.
37. Mihailidou AS, Le TYL, Mardini M, Funder JW. Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction. Hypertension. 2009;54:1306-1312.
38. Mihailidou AS, Buhagiar KA, Rasmussen HH. Na + influx and Na + -K + pump activation during short-term exposure of cardiac myocytes to aldosterone. Am J Physiol Cell Physiol. 1998;274:C175-81.